4.7 Article

Implementation of a novel microarray-based diagnostic test for cancer of unknown primary

期刊

INTERNATIONAL JOURNAL OF CANCER
卷 125, 期 6, 页码 1390-1397

出版社

WILEY
DOI: 10.1002/ijc.24504

关键词

cancer of unknown primary; microarray; molecular diagnostics; gene expression profiling; tumor of unknown origin

类别

向作者/读者索取更多资源

Patients with carcinoma of unknown primary (CUP) present with metastatic disease for which the primary site cannot be found, despite extensive standard investigation. Here, we describe the development and implementation of the first clinically available microarray-based test for this cancer type (CUPPrint), based on 633 individual tumors representing 30 carcinoma and 17 noncarcinoma classes. Tissue of origin prediction for either fresh frozen or paraffin-embedded tumor samples is achieved with the use of a custom 8-pack 1.9k microarray and robust classification algorithm. An expression profile of 495 genes was used to predict tumor origin by applying a k-nearest neighbor algorithm. Internal cross-validation and analysis of an independent, previously published, 229-sample dataset revealed that clinically informative predictions were made for up to 94% of samples analyzed. Analysis of 13 previously published CUP specimens yielded predicted tumor origins that supported the clinical suspicion in 12 cases (92%). Microarray profiling presents a promising tool to assist in the identification of the primary tumor and might direct a more tailored treatment for CUP patients. (C) 2009 UICC

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pathology

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

Lorenza Mittempergher, Leonie J. M. J. Delahaye, Anke T. Witteveen, Jacob B. Spangler, Fariet Hassenmahomed, Sammy Mee, Soufiane Mahmoudi, Jiang Chen, Simon Bao, Mireille H. J. Snel, Sandra Leidelmeijer, Naomi Besseling, Anne Bergstrom Lucas, Carlos Pabon-Pena, Sabine C. Linn, Christa Dreezen, Diederik Wehkamp, Bob Y. Chan, Rene Bernards, Laura J. van't Veer, Annuska M. Glas

JOURNAL OF MOLECULAR DIAGNOSTICS (2019)

Article Oncology

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrinti® Kit at University Hospitals Leuven and Curie Institute Paris

Laurence Slembrouck, Lauren Darrigues, Cecile Laurent, Lorenza Mittempergher, Leonie J. M. J. Delahaye, Isabelle Vanden Bempt, Sara Vander Borght, Liesbet Vliegen, Petra Sintubin, Virginie Raynal, Mylene Bohec, Cecile Reyes, Audrey Rapinat, Celine Helsmoortel, Lynn Jongen, Griet Hoste, Patrick Neven, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Kevin Punie, Els Van Nieuwenhuysen, Sileny Han, Anne Vincent Salomon, Enora Laas Faron, Timothe Cynober, David Gentien, Sylvain Baulande, Mireille H. J. Snel, Anke T. Witteveen, Sari Neijenhuis, Annuska M. Glas, Fabien Reyal, Giuseppe Floris

TRANSLATIONAL ONCOLOGY (2019)

Article Oncology

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

Andreas Schlicker, Architha Ellappalayam, Ines J. Beumer, Mireille H. J. Snel, Lorenza Mittempergher, Begona Diosdado, Christa Dreezen, Sun Tian, Ramon Salazar, Fotios Loupakis, Filippo Pietrantonio, Cristina Santos Vivas, Maria Mercedes Martinez-Villacampa, Alberto Villanueva, Xavier Sanjuan, Marta Schirripa, Matteo Fassan, Antonia Martinetti, Giovanni Fuca, Sara Lonardi, Ulrich Keilholz, Annuska M. Glas, Rene Bernards, Loredana Vecchione

INTERNATIONAL JOURNAL OF CANCER (2020)

Article Oncology

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

Lorenza Mittempergher, Leonie J. M. J. Delahaye, Anke T. Witteveen, Mireille H. J. Snel, Sammy Mee, Bob Y. Chan, Christa Dreezen, Naomi Besseling, Ernest J. T. Luiten, Annuska M. Glas

TRANSLATIONAL ONCOLOGY (2020)

Article Biology

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

Laurent Jacob, Anke Witteveen, Ines Beumer, Leonie Delahaye, Diederik Wehkamp, Jeroen van den Akker, Mireille Snel, Bob Chan, Arno Floore, Niels Bakx, Guido Brink, Coralie Poncet, Jan Bogaerts, Mauro Delorenzi, Martine Piccart, Emiel Rutgers, Fatima Cardoso, Terence Speed, Laura van't Veer, Annuska Glas

COMMUNICATIONS BIOLOGY (2020)

Article Oncology

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart, Laura J. van 't Veer, Coralie Poncet, Josephine M. N. Lopes Cardozo, Suzette Delaloge, Jean-Yves Pierga, Peter Vuylsteke, Etienne Brain, Suzan Vrijaldenhoven, Peter A. Neijenhuis, Sylvian Causeret, Tineke J. Smilde, Giuseppe Viale, Annuska M. Glas, Mauro Delorenzi, Christos Sotiriou, Isabel T. Rubio, Sherko Kummel, Gabriele Zoppoli, Alastair M. Thompson, Erika Matos, Khalil Zaman, Florentine Hilbers, Debora Fumagalli, Peter Ravdin, Susan Knox, Konstantinos Tryfonidis, Aleksandra Peric, Bart Meulemans, Jan Bogaerts, Fatima Cardoso, Emiel J. T. Rutgers

Summary: The MINDACT trial demonstrated that patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy had excellent 5-year distant metastasis-free survival. The long-term follow-up results, including exploratory analysis by age, further support the use of genomic testing in identifying patients who can forgo chemotherapy. Chemotherapy showed different effects on distant metastasis-free survival based on age and nodal status, especially in hormone receptor-positive, HER2-negative disease.

LANCET ONCOLOGY (2021)

Article Medicine, Research & Experimental

Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision

Ryan Van Laar, Samuel King, Richard McCoy, Mirette Saad, Sian Fereday, Ingrid Winship, Catherine Uzzell, Anthony Landgren

Summary: The study evaluated the MEL38 signature in tissue biopsies representing various stages of melanoma, showing that the MEL38 score is a reliable metric for melanoma status, accurately stratifying high-risk and low-risk melanomas. The inclusion of the MEL38 score in routine clinical practice could provide personalized genomic information about skin lesions and improve diagnostic accuracy and patient outcomes.

BIOMARKERS IN MEDICINE (2021)

Article Oncology

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients

Josien C. Haan, Rajith Bhaskaran, Architha Ellappalayam, Yannick Bijl, Christian J. Griffioen, Ersan Lujinovic, William M. Audeh, Frederique Penault-Llorca, Lorenza Mittempergher, Annuska M. Glas

Summary: MammaPrint and BluePrint gene signatures can stratify early-stage breast cancer patients into risk groups, with MammaPrint further dividing into four subgroups. Pathway expression profiles of low and high-risk patients show differences, reflecting proliferative and metastatic characteristics.

GENES CHROMOSOMES & CANCER (2022)

Article Oncology

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial

Josephine M. N. Lopes Cardozo, Caroline A. Drukker, Emiel J. T. Rutgers, Marjanka K. Schmidt, Annuska M. Glas, Anke Witteveen, Fatima Cardoso, Martine Piccart, Laura J. Esserman, Coralie Poncet, Laura J. van't Veer

Summary: Through studying patients with a 70-gene signature ultralow-risk breast cancer, it was found that these patients have excellent prognosis, with an 8-year breast cancer-specific survival rate above 99%, suggesting that they could be candidates for further de-escalation of treatment to avoid overtreatment and the risk of side effects.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer

Jennifer A. Crozier, Julie Barone, Pat Whitworth, Abraham Cheong, Robert Maganini, Jose Perez Tamayo, Patricia Dauer, Shiyu Wang, William Audeh, Annuska M. Glas

Summary: The study aimed to evaluate the concordance of MammaPrint and BluePrint results between preoperative core needle biopsy (CNB) and surgical resection (SR) samples for breast cancer. The findings indicate high concordance between CNB and SR samples for both MammaPrint risk classification and BluePrint molecular subtyping.

JOURNAL OF SURGICAL ONCOLOGY (2022)

Article Oncology

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

M. Opdam, V van der Noort, M. Kleijn, A. Glas, I Mandjes, S. Kleiterp, F. S. Hilbers, D. T. Kruger, A. D. Bins, P. C. de Jong, P. P. J. B. M. Schiphorst, T. van Dalen, B. Flameling, R. C. Rietbroek, A. Beeker, S. M. van den Heiligenberg, S. D. Bakker, A. N. M. Wymenga, I. M. Oving, R. M. Bijlsma, P. J. van Diest, J. B. Vermorken, H. van Tinteren, S. C. Linn

Summary: The aim of this study was to validate the effectiveness of the 70-gene signature in endocrine therapy decision making. The results showed that postmenopausal node-negative ER+HER2- patients with an ultralow-risk 70-gene signature score had excellent 10-year distant recurrence-free interval after surgery with a median of 1 year of endocrine treatment.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Oncology

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance

Midas M. Kuilman, Architha Ellappalayam, Andrei Barcaru, Josien C. Haan, Rajith Bhaskaran, Diederik Wehkamp, Andrea R. Menicucci, William M. Audeh, Lorenza Mittempergher, Annuska M. Glas

Summary: This study identifies and examines dual subtype tumors in early-stage breast cancer using the Purpose BluePrint test, revealing distinct biological characteristics and treatment response differences between different subtypes.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Dermatology

Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma

Ryan Van Laar, Babak Latif, Sam King, Christopher Love, Nadine Taubenheim, Esha Kalanooriya, Wandi Wang, Mirette Saad, Ingrid Winship, Anthony Azzi, Alister Lilleyman, Tony Landgren

Summary: This study validated a circulating microRNA signature (MEL38) for diagnosing invasive melanoma and developed a complementary prognostic microRNA signature (MEL12) that predicts sentinel lymph node status, clinical stage, and survival probability.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Multidisciplinary Sciences

Obesity-associated changes in molecular biology of primary breast cancer

Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt

Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.

NATURE COMMUNICATIONS (2023)

Meeting Abstract Oncology

BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidance

A. Ellappalayam, M. Kuilman, L. Mittempergher, D. Wehkamp, B. Chan, R. Bhaskaran, A. Glas

EUROPEAN JOURNAL OF CANCER (2020)

Article Oncology

Anal cancer screening results from 18-to-34-year-old men who have sex with men living with HIV

Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa

Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.

INTERNATIONAL JOURNAL OF CANCER (2024)